What a large real-world study found about GLP-1 therapies and gallbladder safety

If you are weighing a GLP-1 medication and wondering about effects on the gallbladder and pancreas, this study speaks directly to that question. It was published in the Journal of Clinical Medicine, and it looks at real patient records rather than a laboratory experiment. This is human data, not animal or cell research.

The design is a retrospective propensity score-matched cohort study. In plain terms, the researchers used a large network of existing medical records and then statistically matched patients so the groups being compared looked similar on measurable characteristics. That matching is meant to make a fair comparison, but it is not the same as a randomized trial.

What the researchers studied

The team used the TriNetX Global Collaborative Network to study adults who had both obesity and type 2 diabetes and who had no prior biliary or pancreatic disease. They set up two comparisons that were decided in advance. First, GLP-1 receptor agonists, meaning semaglutide or tirzepatide, versus DPP-4 inhibitors, a different class of diabetes medication. Second, a head-to-head look at tirzepatide versus semaglutide.

The main outcome they tracked was new gallstones, called cholelithiasis, at one year. Secondary outcomes included cholecystitis, which is gallbladder inflammation, cholangitis, acute pancreatitis, and cholecystectomy, which is gallbladder removal surgery. They estimated risk using hazard ratios, where a number below 1 suggests lower risk in the first group listed.

What they reported

The matched groups were large. Each GLP-1 and DPP-4 inhibitor cohort included 281,283 patients, and each tirzepatide and semaglutide cohort included 242,876 patients. Compared with DPP-4 inhibitors, GLP-1 therapy was associated with lower risks across every outcome measured: gallstones (1.02% versus 1.16%), cholecystitis, cholangitis, acute pancreatitis, and gallbladder removal.

In the direct comparison, semaglutide was associated with higher risks of gallstones and cholecystitis than tirzepatide. For pancreatitis, cholangitis, and gallbladder removal, the two did not differ significantly. The authors described tirzepatide as having a modestly more favorable biliary safety profile and concluded that the findings support the overall hepatobiliary safety of these therapies.

What this does and does not establish

This study is about safety signals for specific gallbladder and pancreas events, not about weight or blood sugar results. It does not tell you how any medication would work for you, and it makes no efficacy claims. Associations found in matched records describe patterns across large groups, not what will happen to a given person.

It also cannot prove cause and effect. Even careful matching can leave out factors the records did not capture, which is a known limitation of this kind of observational research. The numbers are relative comparisons between groups, so a lower hazard ratio does not mean an event cannot happen. Outcomes vary by individual.

One honest limitation

Because this is a retrospective analysis of existing records rather than a randomized trial, unmeasured differences between patients may still influence the results. The study reports what was associated with each treatment, not a definitive conclusion about why. Results like these are a reason to talk with a clinician, not a reason to self-select a medication.

If you are considering care

Both medications studied here are ones Live Vital works with: tirzepatide and semaglutide. Each is physician-prescribed and reviewed by Dr. Patrick Taylor, MD, and a prescription is never guaranteed.

This article is general information, not medical advice. A physician decides whether any treatment is appropriate after a full medical intake and physician approval. You can begin that process at get started or book a free consult at consult.